secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ainos, Inc. (AIMD)
CIK:        0001014763
Form:       8-K
Filed at:   2024-12-04T23:59:59+00:00
Accession:  0001493152-24-048611
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ainos signs non-binding MOU with Taiwan Tanabe for VELDONA manufacturing and Taiwan market
--------------------------------------------------------------------------------

- Non-binding MOU with Taiwan Tanabe Seiyaku (Mitsubishi Tanabe subsidiary) for exclusive marketing, manufacturing, and marketing authorization of VELDONA in Taiwan.
- Exclusive right of first negotiation for 3 months from Nov 27, 2024, extendable by 3 months with mutual written notice.
- License fees, milestones, and profit-sharing to be agreed in future definitive agreement, contingent on VELDONA NDA approval in Taiwan.
- VELDONA is low-dose oral interferon-alpha for Sjögren's syndrome; prior studies showed symptom alleviation and good safety profile.
- Ainos believes partnership will accelerate global market entry; Sjögren's syndrome market projected billions in 5 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1014763/000149315224048611/0001493152-24-048611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1014763/000149315224048611/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-048611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer